# FDA Inspection 1200223 - Octapharma Plasma, Inc. - March 16, 2023

Source: https://www.keypedia.com/records/fda_inspections/octapharma-plasma-inc/0c6deaf3-cf3b-4b92-af56-02dc5ea7daa9
Source feed: FDA_Inspections

> FDA Inspection 1200223 for Octapharma Plasma, Inc. on March 16, 2023. Classification: No Action Indicated (NAI).

---

## Details

- Record Type: FDA Inspection
- Inspection ID: 1200223
- Company Name: Octapharma Plasma, Inc.
- Inspection Date: 2023-03-16
- Classification: No Action Indicated (NAI)
- Project Area: Blood and Blood Products
- Product Type: Biologics
- Office Name: Center for Biologics Evaluation and Research

## Related Documents

- [FDA Inspection 1286076 - 2025-10-08](https://www.keypedia.com/records/fda_inspections/octapharma-plasma-inc/23b2a1bb-4bf3-451f-98c5-2311a09ea017)
- [FDA Inspection 1286076 - 2025-10-08](https://www.keypedia.com/records/fda_inspections/octapharma-plasma-inc/ec8b2e29-01ee-4969-a1c3-8ee8045cf538)
- [FDA Inspection 1200223 - 2023-03-16](https://www.keypedia.com/records/fda_inspections/octapharma-plasma-inc/6c564656-8d12-471b-80fe-356764291d22)

Company: https://www.keypedia.com/companies/octapharma-plasma-inc/45ba6fea-f77c-473c-ab67-8e578c517e6d

Office: https://www.keypedia.com/offices/center-for-biologics-evaluation-and-research/dd9e8ea7-6f04-4ed1-b0d7-e7e6b264570d